The immunotherapy of lung cancer
10.3760/cma.j.issn.1673-422X.2015.10.016
- VernacularTitle:肺癌的免疫治疗
- Author:
Shujuan ZHANG
;
Jianhua CHANG
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Immunity,passive;
Antibody,monoclonal
- From:
Journal of International Oncology
2015;(10):776-779
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is characterized by high malignancy and the majority of patients are diagnosed at the advanced or late stage.Chemoradiotherapy has insufficient effect on this malignant tumor.At present the immune therapy has become a new choice for lung cancer treatment.Ipilimumab,antibody to programmed death-1 ,immune cells,cytokines,melanoma-associated antigen A3 vaccine,liposomal BLP25,belagen-pumatucel-L and polypeptide vaccine have been proved effective for lung cancer through various clinical trials. Futhermore,most of them have been moved forward to phase Ⅲ clinical trials in order to get more strong evidence to support the immunotherapy incorporated into the multidisciplinary treatment of lung cancer.
